Daratumumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2326 publications

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia.

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia.

Journal: Kidney medicine

Published: June 15, 2026

Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.

Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.

Journal: Leukemia & lymphoma

Published: June 07, 2026

Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant.

Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant.

Journal: Kidney medicine

Published: June 04, 2026

Recent advances in management of systemic AL amyloidosis

Recent advances in management of systemic AL amyloidosis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: June 03, 2026

Recent topics in smoldering multiple myeloma: early intervention or active monitoring?

Recent topics in smoldering multiple myeloma: early intervention or active monitoring?

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: June 03, 2026

A Single Center Real-World Study of the Efficacy of Daratumumab-Based Regimens in the Treatment of Relapsed/Refractory Multiple Myeloma Patients

A Single Center Real-World Study of the Efficacy of Daratumumab-Based Regimens in the Treatment of Relapsed/Refractory Multiple Myeloma Patients

Journal: Zhongguo shi yan xue ye xue za zhi

Published: June 02, 2026

Response to comment on "Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study".

Response to comment on "Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: June 01, 2026

Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report.

Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report.

Journal: Kidney medicine

Published: June 01, 2026

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2026

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: May 25, 2026

Immunity-oriented drug strategies for viral encephalitis: Acyclovir, antiepileptics and corticosteroids in neurological intensive care.

Immunity-oriented drug strategies for viral encephalitis: Acyclovir, antiepileptics and corticosteroids in neurological intensive care.

Journal: Pakistan journal of pharmaceutical sciences

Published: May 22, 2026

Showing 1-12 of 2,326

Last Updated: 06/30/2026